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Purpose: To investigate the association of
matrix metalloproteinase-9 (MMP-9) and
paraoxonase 1 (PON1) 192 polymorphisms
with susceptibility to coronary artery steno-
sis (CAS) and the number of diseased
vessels in patients with CAS. Methods:
The study population comprised 302
unrelated Iranian individuals, including 145
patients with CAS and 157 control subjects.
Genotypes for MMP-9 and PON1 192
polymorphisms were determined by poly-
merase chain reaction (PCR) and restriction
fragment length polymorphism (RFLP).
Results: In our study, distributions of the
TT genotype of MMP-9 and the RR geno-
type of PON1 192 were significantly higher
in patients compared with healthy control
subjects (Po0.05). Subsequent analysis
demonstrated that a significant difference
existed in the male (TT1TC vs. CC and
RR1QR vs. QQ, Po0.01) but not in the
female. The associations of these poly-
morphisms with the severity of stenosis were
also evaluated, which according to results
distribution of MMP-9 and PON1 192 geno-
types were not significantly different com-
pared with the severity of stenosis (P40.05).
Conclusions: The observation indicates that
the polymorphisms in the MMP-9 and PON1
192 genes potentially play a role in the
manifestation of coronary atherosclerosis but
does not have any effect on the number of
diseased vessels in Iran. J. Clin. Lab. Anal.
24:305–310, 2010. r 2010 Wiley-Liss, Inc.
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INTRODUCTION
Several studies have suggested that either paraoxo-
nase-1 (PON1) or matrix metalloproteinases (MMPs)
are associated with oxidative stress (1,2). It has been
indicated that high-density lipoprotein (HDL) inhibits
oxidation of LDL and thus may protect against risk of
coronary artery disease (CAD) (3,4). The ability of
HDL to prevent the oxidation of LDL has been
attributed to several HDL-associated enzymes, namely
paraoxonase (PON1) (5–7), platelet-activating factor
acetyl hydrolase (8), and lecithin:cholesterol acyltrans-
ferase (9). PON1 is an enzyme with a molecular mass of
43 kDa (354 amino acids) and in serum it is exclusively
located on HDL (10). PON1 has two common coding
polymorphisms: a methionine-to-leucine substitution at
codon 55 (M/L55) and a glutamine-to-arginine substitu-
tion at position 192 (Q/R192). Both polymorphisms
have been associated with a number of pathophysiolo-
gical conditions (11). MMP9 (also known as 92-kDa
type IV collagenase or gelatinase B) possesses proteo-
lytic activity on elastin as well as other basement
membrane proteins including fibronectin, laminin, and
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type IV collagen that surrounds every vascular smooth
muscle cell and underlies the endothelium in the blood
vessel wall (12). Studies have shown that MMP9 plays a
key role in vascular smooth muscle cell migration and
macrophage infiltration in atherogenesis, both of which
requires degradation of the basement membrane (13,14).
A number of polymorphisms in the MMP9 gene have
been identified (15): 1562C/T, a CA repeat,16C/T and
the coding R279Q. In vitro experiments have showed
that the T-1562 allele has higher promoter activity in
driving gene expression than the C-1562 allele (16).
Although epidemiologic studies suggest that several
genetic variants increase the risk of CAD, the associa-
tion studies that examine many polymorphisms simul-
taneously are required to allow reliable prediction of the
genetic risk of CAD. Therefore, this study was designed
as a case–control study in a sample of Iranian subjects
undergoing diagnostic coronary angiography to inves-
tigate the correlation of the MMP9 C/T and PON1 Q/
R192 gene polymorphisms with the incidence and
severity of coronary artery stenosis (CAS).
MATERIALS AND METHODS
Study Subjects
The cases and controls were selected by simple
sampling from unrelated individuals. One hundred
forty-five patients (75 male, 70 female; mean age:
58.4179.12) and 157 healthy individuals (80 male, 77
female; mean age: 55.3579.43) were entered into this
study. Patients were selected from Shahid Rajaee
Hospital (Tehran, Iran) and Shahid Madani Hospital
(Tabriz, Iran) if they had CAD, which was defined as
coronary stenosis of450% in at least one major
coronary artery in the angiography performed after a
clinical suspicion. Those with coronary stenosis less than
50% were excluded from the study. Severity of CAD
was determined by the number of coronary arteries
involved (single vessel disease, double vessel disease, and
triple vessel disease).
Healthy individuals were those without history of
angina pectoris who had never been treated for coronary
diseases. Individuals with hepatic or renal disease,
cardiomyopathy, congestive heart failure, acute myo-
cardial infarction within the last 3 months, diabetes
mellitus, hypertension, hyperlipidemia, and those who
worked with insecticides were excluded from the study.
A questionnaire was completed for all patients and
controls to collect data regarding their demography,
medical status and history, and family history. Blood
pressure, weight, and height were also recorded. This
study was approved by the University Hospital Ethics
Committee a and written informed consent was
obtained from all patients and control subjects.
Laboratory Measurements
Serum from samples were used to estimates lipid
levels. Total cholesterol (TC), HDL, HDL-cholesterol,
and triglyceride concentrations were calculated using
Friedewald formula (17).
Determination of Genotypes
Genomic DNA was extracted from peripheral blood
leukocytes by the salting-out method (18). Polymerase
chain reaction (PCR)-restriction fragment length poly-
morphism (RFLP) was used to determine the MMP9
and PON1 polymorphisms. PCR primers used in the
current study are listed in Table 1. Genomic DNA was
amplified in 50 ml of mixture containing 300 ng of DNA
template, 0.4 mmol/l each primers, 200 mmol/l dNTPs,
5 ml of 10 reaction buffer, and 1.25u Taq DNA
polymerase. The PCR cycling conditions were 2min at
951C followed by 35 cycles of 45 s at 941C, 75 s at 651C
(MMP-9) or 45 s at 641C (PON1), and 60 s at 721C, and
with a final extension at 721C for 10min. PCR products
was digested for 16 h at 371C (MMP-9) or for 8 h at
371C (PON1) in a 15-ml reaction containing 5U Mse1
and Alw1 restriction enzymes (New England Biolabs,
Ipswich, MA), respectively, for the determination of
MMP-9 and PON1 genotypes. The digested products
were subjected to gel electrophoresis and visualized using
ethidium bromide staining. The sizes of PCR products of
MMP-9 and PON1 were 435 and 99bp, respectively. The
MMP9 C alleles were represented by a band of 435bp
and the T alleles were represented by two bands of 244
and 191 bp, whereas heterozygotes displayed a combina-
tion of both (435, 247, and 188bp). For the PON1 SNP,
the Q alleles were expected as a band of 99bp, the R
alleles with two bands of 65 and 34bp, and the
heterozygotes show both alleles (99, 65, and 34bp).
TABLE 1. Sequences of PCR Primers
Gene Polymorphism Forward primer (50–30) Reverse primer (50–30)
MMP-9 C/T GCCTGGCACATAGTAGGCCC CTTCCTAGCCAGCCGGCATC
PON1 Q/R TATTGTTGCTGTGGGACCTGAG CACGCTAAACCCAAATACATCTC
MMP, matrix metalloproteinase; PCR, polymerase chain reaction; PON1, paraoxonase1.
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All assays were conducted blindly by two researchers
without the knowledge of case or control status.
Additionally, approximately 10% of the samples were
randomly selected and retested, and the results were
100% concordant.
Statistical Analysis
Student’s t-test was used for comparison of age, BMI,
and lipid profile in control and patient groups. Genotype
frequencies were compared by the w2 test. Allele frequen-
cies were determined by the gene counting method, and
Hardy–Weinberg equilibrium was tested by the w2 test.
The relationship between MMP9/PON1 genotypes and
severity of disease in patient group was evaluated by the
w2 test. All the calculations were performed using the SPSS
14 program (SPSS for Windows, Chicago, IL).
RESULTS
Table 2 summarizes the clinical profiles of all
participants according to the coronary angiogram. All
the baseline characteristics of the two groups are quite
similar. The distributions of genotypes and alleles for
MMP9 C/T and PON1 Q/R 192 in patients and control
subjects are presented in Table 3. The genotype
distributions satisfied the Hardy–Weinberg equilibrium.
Significant differences were observed in the frequency of
MMP9 and PON1 genotypes between controls and
patients. Patients with CAS had a higher frequency of
the TT and RR genotypes than the control group
(Po0.05). According to genotype data, there was a
significantly higher frequency of 1562 T allele of
MMP9 SNP and R allele of PON1 in patients compared
with controls (Table 3; Po0.05). Subsequent analysis of
either gender participants shows that in males the T and
R alleles frequency were significantly higher in the
patient group (TT1TC vs. CC and RR1RQ vs. QQ
Po0.01), whereas in females, it is similar in both groups
(Tables not shown). When the frequencies of genotype
and alleles of MMP-9 and PON1 were compared with
the number of diseased vessels, frequencies of the TT
genotype and the T allele of MMP-9 were lower, and the
frequency of the C allele was higher, in patients with one
vessel compared with patients with two or three diseased
vessels (Table 4); however, this difference was not
statistically significant owing to the small number of
subjects in each genotype (P40.05). PON1 gene
variants were not associated with the number of
diseased vessels (P40.05).
DISCUSSION
In this study, we evaluated the distribution of MMP9
C/T and PON1 Q/R192 genotypes in angiographically
TABLE 2. Classical Coronary Risk Factors and Lipid Profile
in Patient and Control Subjects
a
Variable Control group Patient group P-value
Age (year) 55.3579.43 58.4179.12 NS
Sex (male/female) (80/77) (75/70) NS
BMI (kg/m2) 27.2474.06 26.1474.52 NS
SBP (mm hg) 12.3571.33 12.7571.32 NS
DBP (mm hg) 7.6770.54 7.7370.34 NS
Cholestrol(mg/dl) 172.43736.76 177.12738.65 0.17
Triglyceride (mg/dl) 145.31761.54 156.23764.34 0.23
HDL-C (mg/dl) 38.4479.04 37.8579.19 NS
LDL-C (mg/dl) 94.14729.53 96.13723.13 NS
VLDL-C (mg/dl) 39/01721.17 41.12720.40 NS
Po0.05 was considered statistically significant. F/M, females/males;
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic
blood pressure; TC, total cholesterol; TG, triglycerides; HDL-C, high-
density lipoprotein cholesterol; VLDL-C, very low-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein cholesterol.
aData are presented as mean7SD.
TABLE 3. The Genotypes Distributions of the MMPs





MMP-9 TT 77 (52.93) 62 (40.56) o0.05
TC 57 (39.65) 76 (46.25)
CC 11 (7.42) 19 (13.19)
TC1TT 134 (92.41) 138 (87.89)
T 211 (72.76) 200 (63.70)
C 79 (27.24) 114 (36.30)
PON1 QQ 42 (28.56) 73 (45.58) o0.01
QR 71 (49.77) 66 (43.87)
RR 32 (21.67) 18 (10.55) o0.05
QR1RR 103 (71.03) 84 (53.50)
Q 155 (53.45) 212 (67.51)
R 135 (46.55) 102 (32.49)
MMP, matrix metalloproteinase; PON1, paraoxonase1.
TABLE 4. MMP-9, and PON1 192 Polymorphisms Compared
With the Number of Diseased Vessels in Patients
One vessels Two vessels Three vessels
Gene Genotype n (%) n (%) n (%)
TT 9 (34.61) 17 (41.46) 32 (41.03)
TC 5 (19.24) 10 (24.30) 17 (21.80)
MMP-9 CC 12 (46.15) 14 (34.14) 29 (37.18)
T 23 (44) 44 (54) 81 (64)
C 29 (56) 38 (46) 45 (36)
QQ 19 (33.93) 8 (23.53) 16 (29)
QR 25 (44.65) 22 (64.70) 25 (45.45)
PON1 RR 2 (21.42) 4 (11.77) 14 (25.45)
Q 63 (56) 38 (56) 57 (52)
R 49 (44) 30 (44) 53 (48)
MMP, matrix metalloproteinase; PON1, paraoxonase1.
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defined CAD patients and control subjects and found
these polymorphisms as a risk factor for atherosclerosis.
However, as the sampling method was simple, the cases
and controls are not true representative of the ethnically
mixed Iranian population. Accordingly, the results may
not be applicable to some Iranian ethnical groups. Our
study shows that the frequency of the 1562 T allele of
MMP-9 and the 192 R allele of PON1 in CAD patients
were significantly higher than that in healthy controls.
Transfection experiments and DNA–protein interac-
tion assays indicated that the T allele had higher activity
(19,20). Several studies indicate that the T allele has also
been associated with complicated coronary lesions, and
carriers of the T allele had greater levels of MMP9
mRNA and protein, and stiffer large arteries (20,21).
MMP9 knockout studies in mice have also demon-
strated a role of MMP9 in the development of
atherosclerosis (22). Compared with MMP9 wild-type
mice, MMP9-deficient mice have fewer and smaller
atherosclerotic lesions (23). Smooth muscle cell migra-
tion into the intima is reduced in MMP9-deficient mice
(14,24) and atherosclerotic lesions in MMP9-deficient
mice contain fewer macrophages (23). Thus, increased
vascular smooth muscle migration and macrophage
infiltration are likely a mechanism that, at least partly,
explains the finding of increased coronary atherosclero-
sis in carriers of the MMP9 high expression T-1562
allele in humans and this mechanism may explain why in
our study the MMP9 T allele has been found to be
present at an increased frequency in CAD.
There is a 10- to 40-fold difference in serum
paraoxonase activity among individuals, as assessed by
the enzyme’s ability to hydrolyze exogenous, non
physiological substrates. The glutamine (Q) to arginine
(R) substitution at position 192 independently influence
PON1 activity and have been defined as the part of the
molecular basis for this inter-individual variability (25).
It has been shown that the PON1 R allozyme is
less efficient at retarding the oxidation of LDL than is
the Q allozyme because of the decreased hydrolysis of
lipid peroxides by the R allozyme (26,27). This finding
may explain why in our study the PON1 R allele has
been found to be present at an increased frequency in
CAD.
Morever, this study demonstrated that without con-
sidering other risk factors, PON1 192 and MMP9
polymorphisms are not related to severity of CAS.
Although this finding seems a little unusual, it must be
noted that polymorphisms consist only a part of
variations of PON1 enzymatic activity and beside genetic
factors, enzyme activity was influenced by acquired and
environmental factors, such as diet, life style (smoking,
alcohol drinking,y), environmental chemical material,
age, sex and other different factors (28).
Previous studies have investigated the association
between MMP9 and PON1 192 polymorphisms and
CAD. Evidence from genetic epidemiological studies
indicates that individuals carrying the T-1562 allele are
predisposed to the development of coronary athero-
sclerosis that results in significant coronary stenosis
(15,16). In addition, an autopsy study by Pollanen et al.
shows that carriers of the T-1562 allele have larger
atheromas than non-carriers, and this difference is more
pronounced in older people (29). Transfection experi-
ments and DNA–protein interaction assays indicated
that the T allele had higher activity (29,30). Several
studies indicate that the T allele has also been associated
with complicated coronary lesions, and carriers of the
T allele had greater levels of MMP9 mRNA and protein,
and stiffer large arteries (30,31).
In 81 stroke patients who were compared with 2553
control subjects, PON1R was shown to be an indepen-
dent risk factor for stroke (32). Similarly, in a case–
control study of 139 CAD patients and 119 control
subjects, RR genotype not only defined as an indepen-
dent risk factor for CAD but also as a factor that related
with the severity of disease (33). In accordance with our
study, in these studies, the QQ genotype was the most
common genotype among control subjects, whereas QR
genotype was the most common among CAD patients.
However, in the study by Pasdar et al. that was
performed in 397 stroke patients and 400 control
subjects, no association could be found between stroke
and PON1 gene polymorphisms, suggesting no association
between this disease and variations in PON1 alleles (34).
Finally, in the study by Flekac et al. who compared
diabetic patients (some of this patients had macrovas-
cular complications) and control subjects found a
statistically significant difference in the distribution of
PON1 genotypes or alleles between CAD patients and
controls (35); but, on the contrary of our study,
homozygosity of PON1 for the Gln allele (QQ) showed
lower antioxidant activity and found to be an indepen-
dent risk factor for CHD.
First possible explanations of these discrepancies may
be the variability of population selection and study
design. Furthermore, large differences between ethnic
populations are known in the PON1 genotype distribu-
tion, which may be the other reason for differences
among studies (36). Finally, it must be noted that, in
general, the RR genotype has high paraoxonase activity
and the QQ genotype has low activity (35). However, the
antioxidant capacity of PON1 is not always identical to
PON1 enzymatic activity and the PON1 genotype,
which may cause the controversial association of
PON1 with CAD. Although it has been shown that
the RR genotype is less efficient at hydrolyzing LDL
peroxides and this finding may explain why in this study
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and some other studies the paraoxonase RR genotype
has been found at an increased frequency in patient
group (37,38), recently it has been defined that the
PON1-192Q binds HDL with a 3-fold lower affinity
than the R isozyme and consequently exhibits signifi-
cantly reduced stability, lipolactonase activity, and
macrophage cholesterol efflux (38). It has also been
shown that impairing the lactonase activity of PON1,
through mutations of its catalytic dyad, diminishes
PON1’s ability to prevent LDL from oxidation (39) and
the findings of the recent clinical study complete these
results, demonstrating that individuals with the arginine
(R) mutation at position 192 have higher serum levels of
PON1 activity (40). These studies indicate that despite
partially expanding researches, yet the mechanism of
antioxidant activity of PON1 and spatially this fact that
which of the PON1 genotypes has higher antioxidant
activity is not well defined and this issue may be one of
the other probable differences in the results of different
studies.
There were several limitations for our study. First, this
was a small study, and these observations must be
confirmed in a larger sample of patients. Nevertheless, a
large-scale prospective study should be launched to
confirm the associative effect of these polymorphisms
with CAS patients. Second, we analyzed only two
polymorphisms in most of the genes, which could have
missed an association that was to a specific polymorph-
ism. It will be interesting also to see whether these
polymorphisms have a role in the manifestation and
development of other CAD such as myocardial infarc-
tion, coronary aneurysm, etcy
The results of this study can potentially help in the
identification of people at higher risk of development
of coronary heart disease. It might be possible to
develop a genetic risk calculator using a profile of
known genetic markers, including those described
here, to determine each individual’s genetic risk. If
the risk is high, employment of strict atherosclerosis
preventive measures starting from the young age can
theoretically decrease the incidence and prevalence of
this disease.
In conclusion, the MMP9 T allele and PON1 R allele
are associated with CAS. Atherosclerosis is a complex
disease that depends on multiple factors, including
genetic, dietary, environmental, and pharmacological
factors (41). In this study, we evaluated only one factor
in the pathogenesis of this disease i.e. the polymorphism
of a single related gene that is one of several factors
involved in this complex disease and as there are some
different factors to cause this disease as well as its
severity, it is suggested that although in our study
PON1RR genotype and MMP9 TT genotype has been
found as a risk factor for stenosis but there are,
probably, more important factors rather than poly-
morphism, involved in the severity of the disease.
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